

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

POWER OF ATTORNEY BY ASSIGNEE	Attorney Docket	UCSF-085CIP
	First Named Inventor	Nadel, et al.
	Application Number	09/616,223
	Filing Date	July 14, 2000
	Examiner Name (Group Art Unit)	N/A
	Title: <i>Preventing Airway Mucus Production By Administration of EGF-R Antagonists</i>	

The Regents of the University of California, assignee of the above-identified application by assignment dated 8-14-00 and 8-17-00, hereby appoints:

BOZICEVIC, FIELD & FRANCIS LLP

Name	Registration No.	Name	Registration No.
Karl Bozicevic	28,807	Pamela J. Sherwood	36,677
Bret E. Field	37,620	Dianna L. DeVore	42,484
Carol L. Francis	36,513	Paula A. Borden	42,344
Alan W. Cannon	34,977	Nicole Verona	P47,153

as its attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the Patent and Trademark Office connected therewith.


DIRECT ALL CORRESPONDENCE TO:

Individual Name	Paula A. Borden		
Firm Name	BOZICEVIC, FIELD & FRANCIS LLP		
Address	200 Middlefield Road, Suite 200		
City, State, Zip	Menlo Park, California 94025		
Country	U.S.A.		
Telephone	(650) 327-3400	Facsimile	(650) 327-3231

SIGNATURE of Assignee of Record

In accordance with 37 CFR §3.73(b) I hereby certify that I am empowered to act on behalf of the Assignee of the above-identified patent application. The original Assignment is concurrently being forwarded to the Assignment Branch of the U.S. Patent Office for recordation.

I declare that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code §1001 and that such willful false statements may jeopardize the validity of the above referenced application or any patent resulting from that application.

Name and Company	The University of California, San Francisco		
Title	Susan Nakashima, Business Manager		
Signature		Date	8/20/00

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) <input type="checkbox"/> Declaration Submitted with Initial Filing OR <input checked="" type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16(e)) required)		Attorney Docket Number	UCSF-085CIP
		First Named Inventor	Jay Nadel, et al.
		COMPLETE IF KNOWN	
		Application Number	09/616,223
		Filing Date	July 14, 2000
		Group Art Unit	N/A
		Examiner Name	N/A

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: *Preventing Airway Mucus Production By Administration of EGF-R Antagonists*

the specification of which:

☐ is attached hereto

OR

☒ was filed on July 14, 2000 as United States Application Number or PCT International Application Number 09/616,223 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined by 37 CFR 1.56.

Insofar as the subject matter of each of the claims of this application are not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designating at least one country other than the United States of America, listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) having a filing date before that of the application(s) of which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			—	—	—
			—	—	—
			—	—	—
			—	—	—

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)
60/097,023	08/18/1998

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application(s) designating the United States of America, listed below.							
U.S. Parent Application or PCT Parent Number				Parent Filing Date (MM/DD/YYYY)		Parent Patent Number (if applicable)	
09/375,597				08/17/1999			
DIRECT ALL CORRESPONDENCE TO:							
Name		Paula A. Borden					
Address		BOZICEVIC, FIELD & FRANCIS LLP					
Address		200 Middlefield Road, Suite 200					
City, State, Zip		Menlo Park, California 94025					
Country		U.S.A.		Telephone		650-327-3400	
				Facsimile		650-327-3231	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.							
Name of Sole or First Inventor:							
Given Name (first and middle [if any])				Family Name or Surname			
Jay A.				Nadel			
Inventor's Signature		<i>Jay A. Nadel</i>				Date <i>Aug 14, 2000</i>	
Residence: City		San Francisco		State		CA	
				Country		USA	
Post Office Address		The University of California, San Francisco Cardiovascular Research Institute					
Post Office Address		Department of Medicine 505 Parnassus Avenue, M-1325					
City		San Francisco		State		CA	
				Zip		94143-0130	
				Country		USA	

Name of Second Inventor:							
Given Name (first and middle [if any])				Family Name or Surname			
Kiyoshi				Takeyama			
Inventor's Signature						Date	
Residence: City		Tokyo		State		-	
				Country		JAPAN	
Post Office Address		4-6-1-108, Setagaya					
Post Office Address		Setagaya-ku					
City		Tokyo		State			
				Zip		158-0095	
				Country		JAPAN	

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)		Attorney Docket Number	UCSF-085CIP
		First Named Inventor	Jay Nadel, et al.
Declaration Submitted with Initial Filing <input type="checkbox"/> OR <input checked="" type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16(e)) required)		COMPLETE IF KNOWN	
		Application Number	09/616,223
		Filing Date	July 14, 2000
		Group Art Unit	N/A
		Examiner Name	N/A

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: *Preventing Atrway Mucus Production By Administration of EGF-R Antagonists*

the specification of which:

☐ Is attached hereto

OR

☒ was filed on July 14, 2000 as United States Application Number or PCT International Application Number 09/616,223 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined by 37 CFR 1.56.

Insofar as the subject matter of each of the claims of this application are not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designating at least one country other than the United States of America, listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) having a filing date before that of the application(s) of which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached	
				YES	NO

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)
60/097,023	08/18/1998

Any Dkt No. UCSF-085CIP

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application(s) designating the United States of America, listed below.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
09/375,597	08/17/1999	

DIRECT ALL CORRESPONDENCE TO:


Name	Paula A. Borden				
Address	BOZICEVIC, FIELD & FRANCIS LLP				
Address	200 Middlefield Road, Suite 200				
City, State, Zip	Menlo Park, California 94025				
Country	U.S.A.	Telephone	650-327-3400	Facsimile	650-327-3231

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

Given Name (first and middle (if any))				Family Name or Surname			
Jay A.				Nadel			
Inventor's Signature						Date	
Residence: City	San Francisco	State	CA	Country	USA	Citizenship	USA
Post Office Address	The University of California						
Post Office Address	Department of Medicine 505 Parnassus Avenue, M-1325						
City	San Francisco	State	CA	Zip	94143-0130	Country	USA

Name of Second Inventor:

Given Name (first and middle (if any))				Family Name or Surname			
Kiyoshi				Takeyama			
Inventor's Signature						Date	8/17/2000
Residence: City	San Francisco	State	CA	Country	USA	Citizenship	Japan
Post Office Address	The University of California						
Post Office Address	Department of CVRI 505 Parnassus Avenue, S-1165						
City	San Francisco	State	CA	Zip	94143-0130	Country	USA

F:\DOCUMENT\UCSF (formerly 9076)\085cip\declaration.wpd